Lixte Biotech Hldgs (LIXT) 0.2000 $LIXT
Gaucher's Disease - Pipeline Review, H1 2014
M2 - Thu Jul 03, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p99kr2/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme Corporation - Sangamo BioSciences, Inc. - Shire Plc - Amicus Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Protalix BioTherapeutics, Inc. - JCR Pharmaceuticals Co., Ltd. - greenovation Biotech GmbH - Neuraltus Pharmaceuticals, Inc. - Biosidus S.A. - ExSAR Corporation - Bioorganic Research and Services S.A. - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/p9...rs_disease
Neurofibromatoses Type II - Pipeline Review, H1 2014
M2 - Wed Jun 25, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vq8st6/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type II - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type II pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Lixte Biotechnology Holdings, Inc. - Arno Therapeutics, Inc. - Nexgenix Pharmaceuticals, LLC - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/vq...bromatoses
Medulloblastoma - Pipeline Review, H1 2014
M2 - Wed Jun 25, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ld2gzs/medulloblastoma) has announced the addition of the "Medulloblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Medulloblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medulloblastoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Medulloblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Medulloblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Mentioned: - Archer Biosciences - Conkwest - Lixte Biotechnology Holdings - Novartis - Stemline Therapeutics - Takeda Pharmaceutical - TheraBiologics - ThromboGenics For more information visit http://www.researchandmarkets.com/research/ld...loblastoma
Gaucher's Disease - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 05, 2:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/88zfnr/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2013" report to their offering. 'Gaucher's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gaucher's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gaucher's Disease. Scope - A snapshot of the global therapeutic scenario for Gaucher's Disease. - A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gaucher's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Gaucher's Disease Overview Therapeutics Development Pipeline Products for Gaucher's Disease - Overview Pipeline Products for Gaucher's Disease - Comparative Analysis Gaucher's Disease - Therapeutics under Development by Companies Gaucher's Disease - Therapeutics under Investigation by Universities/Institutes Gaucher's Disease - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Gaucher's Disease - Products under Development by Companies Gaucher's Disease - Products under Investigation by Universities/Institutes Gaucher's Disease - Companies Involved in Therapeutics Development Gaucher's Disease - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles eliglustat tartrate - Drug Profile acetylcysteine - Drug Profile ambroxol - Drug Profile PRX-112 - Drug Profile AT-3375 - Drug Profile JR-101 - Drug Profile NP-003 - Drug Profile imiglucerase Biosimilar - Drug Profile LB-201 - Drug Profile LB-205 - Drug Profile Gluco-Cerebosidase - Drug Profile BNT-001 - Drug Profile Glucocerebrosidase Activators - Drug Profile DOS-000011 - Drug Profile imiglucerase Biosimilar - Drug Profile Companies Mentioned Genzyme Corporation Amicus Therapeutics, Inc. Lixte Biotechnology Holdings, Inc. Protalix BioTherapeutics, Inc. JCR Pharmaceuticals Co., Ltd. greenovation Biotech GmbH Neuraltus Pharmaceuticals, Inc. Biosidus S.A. ExSAR Corporation Bioorganic Research and Services S.A. Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/88...rs_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lixte Biotechnology Announces Initiation of a Materials Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke
PR Newswire - Tue Dec 10, 8:00AM CST
Lixte Biotechnology Holdings, Inc. (OTC: LIXT), a clinical-stage pharmaceutical company, has signed a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS, NIH). Dr. John Kovach, the founder of Lixte said "Under this agreement, the Surgical Neurology Branch of NINDS, NIH, will conduct research characterizing a variety of compounds proprietary to Lixte. This research will examine the compounds' potential for anti-cancer activity, reducing neurological deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases."
Pediatric Cancer - Pipeline Review, H2 2013
M2 - Wed Sep 04, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hd2jzg/pediatric_cancer) has announced the addition of the "Pediatric Cancer - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Pediatric Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pediatric Cancer. Scope - A snapshot of the global therapeutic scenario for Pediatric Cancer. - A review of the Pediatric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pediatric Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Pediatric Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pediatric Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - AEterna Zentaris - Ambit Biosciences Corporation - Antigenics - Astellas Pharma - Boehringer Ingelheim - Crusade Laboratories - Eisai - Incyte Corporation - Innogene Kalbiotech - Lixte Biotechnology Holdings - Marshall Edwards - PharmaMar - Polaris Group - Sanofi-Aventis - Shionogi & Co. - Spectrum Pharmaceuticals - Stemline Therapeutics - SuperGen For more information visit http://www.researchandmarkets.com/research/hd...ric_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Gaucher's Disease - Pipeline Review Report, H1 2013 Edition
M2 - Tue Jun 04, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lv6mcb/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H1 2013" report to their offering. 'Gaucher's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gaucher's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gaucher's Disease. Scope - A snapshot of the global therapeutic scenario for Gaucher's Disease. - A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gaucher's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Gaucher's Disease Therapeutics Development - Genzyme Corporation - Dong-A Pharmaceutical Co., Ltd. - Amicus Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Protalix BioTherapeutics, Inc. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - ISU ABXIS Co.,Ltd. - Bio Sidus S.A. Drug Profiles - eliglustat tartrate - afegostat tartrate - taliglucerase alfa - AT-3375 - taliglucerase alfa - NP-003 - imiglucerase biosimilar - DA-3811 - LB-205 - ambroxol - afegostat tartrate Enzyme Replacement Therapy - ambroxol - PRX-112 - BNT-001 For more information visit http://www.researchandmarkets.com/research/lv...rs_disease
Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
PR Newswire - Thu Apr 25, 8:00AM CDT
Lixte Biotechnology Holdings, Inc. (LIXT), reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere®). Details of the trial underway at an NCI-designated Comprehensive Cancer Center are available in the clinical trials registry: http://clinicaltrials.gov/show/NCT01837667.
Gaucher's Disease - Pipeline Review, H1 2014
M2 - Thu Jul 03, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p99kr2/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme Corporation - Sangamo BioSciences, Inc. - Shire Plc - Amicus Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Protalix BioTherapeutics, Inc. - JCR Pharmaceuticals Co., Ltd. - greenovation Biotech GmbH - Neuraltus Pharmaceuticals, Inc. - Biosidus S.A. - ExSAR Corporation - Bioorganic Research and Services S.A. - Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/p9...rs_disease
Neurofibromatoses Type II - Pipeline Review, H1 2014
M2 - Wed Jun 25, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vq8st6/neurofibromatoses) has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type II - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type II pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Lixte Biotechnology Holdings, Inc. - Arno Therapeutics, Inc. - Nexgenix Pharmaceuticals, LLC - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/vq...bromatoses
Medulloblastoma - Pipeline Review, H1 2014
M2 - Wed Jun 25, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ld2gzs/medulloblastoma) has announced the addition of the "Medulloblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Medulloblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medulloblastoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Medulloblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Medulloblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Mentioned: - Archer Biosciences - Conkwest - Lixte Biotechnology Holdings - Novartis - Stemline Therapeutics - Takeda Pharmaceutical - TheraBiologics - ThromboGenics For more information visit http://www.researchandmarkets.com/research/ld...loblastoma
Gaucher's Disease - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 05, 2:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/88zfnr/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2013" report to their offering. 'Gaucher's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gaucher's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gaucher's Disease. Scope - A snapshot of the global therapeutic scenario for Gaucher's Disease. - A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gaucher's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Gaucher's Disease Overview Therapeutics Development Pipeline Products for Gaucher's Disease - Overview Pipeline Products for Gaucher's Disease - Comparative Analysis Gaucher's Disease - Therapeutics under Development by Companies Gaucher's Disease - Therapeutics under Investigation by Universities/Institutes Gaucher's Disease - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Gaucher's Disease - Products under Development by Companies Gaucher's Disease - Products under Investigation by Universities/Institutes Gaucher's Disease - Companies Involved in Therapeutics Development Gaucher's Disease - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles eliglustat tartrate - Drug Profile acetylcysteine - Drug Profile ambroxol - Drug Profile PRX-112 - Drug Profile AT-3375 - Drug Profile JR-101 - Drug Profile NP-003 - Drug Profile imiglucerase Biosimilar - Drug Profile LB-201 - Drug Profile LB-205 - Drug Profile Gluco-Cerebosidase - Drug Profile BNT-001 - Drug Profile Glucocerebrosidase Activators - Drug Profile DOS-000011 - Drug Profile imiglucerase Biosimilar - Drug Profile Companies Mentioned Genzyme Corporation Amicus Therapeutics, Inc. Lixte Biotechnology Holdings, Inc. Protalix BioTherapeutics, Inc. JCR Pharmaceuticals Co., Ltd. greenovation Biotech GmbH Neuraltus Pharmaceuticals, Inc. Biosidus S.A. ExSAR Corporation Bioorganic Research and Services S.A. Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/88...rs_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lixte Biotechnology Announces Initiation of a Materials Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke
PR Newswire - Tue Dec 10, 8:00AM CST
Lixte Biotechnology Holdings, Inc. (OTC: LIXT), a clinical-stage pharmaceutical company, has signed a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS, NIH). Dr. John Kovach, the founder of Lixte said "Under this agreement, the Surgical Neurology Branch of NINDS, NIH, will conduct research characterizing a variety of compounds proprietary to Lixte. This research will examine the compounds' potential for anti-cancer activity, reducing neurological deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases."
Pediatric Cancer - Pipeline Review, H2 2013
M2 - Wed Sep 04, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hd2jzg/pediatric_cancer) has announced the addition of the "Pediatric Cancer - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Pediatric Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pediatric Cancer. Scope - A snapshot of the global therapeutic scenario for Pediatric Cancer. - A review of the Pediatric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pediatric Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Pediatric Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pediatric Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - AEterna Zentaris - Ambit Biosciences Corporation - Antigenics - Astellas Pharma - Boehringer Ingelheim - Crusade Laboratories - Eisai - Incyte Corporation - Innogene Kalbiotech - Lixte Biotechnology Holdings - Marshall Edwards - PharmaMar - Polaris Group - Sanofi-Aventis - Shionogi & Co. - Spectrum Pharmaceuticals - Stemline Therapeutics - SuperGen For more information visit http://www.researchandmarkets.com/research/hd...ric_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Gaucher's Disease - Pipeline Review Report, H1 2013 Edition
M2 - Tue Jun 04, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lv6mcb/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H1 2013" report to their offering. 'Gaucher's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gaucher's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gaucher's Disease. Scope - A snapshot of the global therapeutic scenario for Gaucher's Disease. - A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gaucher's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Gaucher's Disease Therapeutics Development - Genzyme Corporation - Dong-A Pharmaceutical Co., Ltd. - Amicus Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Protalix BioTherapeutics, Inc. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - ISU ABXIS Co.,Ltd. - Bio Sidus S.A. Drug Profiles - eliglustat tartrate - afegostat tartrate - taliglucerase alfa - AT-3375 - taliglucerase alfa - NP-003 - imiglucerase biosimilar - DA-3811 - LB-205 - ambroxol - afegostat tartrate Enzyme Replacement Therapy - ambroxol - PRX-112 - BNT-001 For more information visit http://www.researchandmarkets.com/research/lv...rs_disease
Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
PR Newswire - Thu Apr 25, 8:00AM CDT
Lixte Biotechnology Holdings, Inc. (LIXT), reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere®). Details of the trial underway at an NCI-designated Comprehensive Cancer Center are available in the clinical trials registry: http://clinicaltrials.gov/show/NCT01837667.
